Pfizer And J&J Settle Remicade Antitrust Litigation
Long-Running Case Over Infliximab Biosimilars Resolved On Confidential Terms
• By David Wallace
Generate a summary of this article
Listen to this article
Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.
Pfizer and J&J have settled the Remicade antitrust lawsuit • Source: Alamy
Antitrust litigation between Pfizer and Johnson & Johnson over US contracts and deals for the Remicade (infliximab) brand that were alleged to have been set up so as to dampen biosimilar competition has been dismissed after the companies settled on confidential terms.
[Sidebar#GB139914]
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.